A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.

Also called NCT05275400

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 986 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05275400
  • EudraCT 2021-002569-16
Other papers using this trial's data
  • Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial Lancet (London, England), 2025-06-28 DOI, PubMed 40562047 PubMed links an erratum for this paper. Erratum: PMID 41109720

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Hungary, Japan, Poland, Puerto Rico, Slovakia, South Korea, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05275400. Randomized; no masking; primary purpose treatment. Start 2022-03-08 (actual); primary completion 2024-05-15 (actual). Results posted on 2025-06-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
Intervention (Drug)
Insulin Efsitora Alfa
Intervention (Drug)
Insulin Degludec
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05275400
Content hash
78ea0b5bd5dafd1b30a29de860bcb1d46b6e4bc2464e5418b1377c2c4202bf28